Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Arlene B. Chapman(Emory University), David C. Wheeler(University College London), Tess Harris(Polycystic Kidney Disease Foundation), Roser Torrá(Universitat Autònoma de Barcelona), Olivier Devuyst(Cliniques Universitaires Saint-Luc), Dwight Odland, York Pei(University Health Network), Kai‐Uwe Eckardt(Friedrich-Alexander-Universität Erlangen-Nürnberg), Ron T. Gansevoort(University Medical Center Groningen), Vicente E. Torres(Mayo Clinic in Arizona), Shigeo Horie(Juntendo University), Ronald D. Perrone(Tufts Medical Center), Terry Watnick(University of Maryland, Baltimore), Bertram L. Kasiske(University of Minnesota), Robert W. Schrier(University of Denver), Yves Pirson(Cliniques Universitaires Saint-Luc)
Cited by 602
Related Papers
K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
|Data Archiving and Networked Services (DANS)|2002|11.7k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification
|Annals of Internal Medicine|2003|4.6k